One dose vaccination with Mycoplasma hyopneumoniae

Abstract

The present invention relates to methods for treating or preventing a disease or disorder in an animal caused by infection by Mycoplasma hyopneumoniae (M. hyo) by administering to the animal at approximately three (3) to ten (10) days of age, a single dose of an effective amount of a M. hyo vaccine. The M. hyo vaccine can be a whole or partial cell inactivated or modified live preparation, a subunit vaccine, or a nucleic acid or DNA vaccine. The M. hyo vaccine administered in accordance with the present invention can be synthesized or recombinantly produced.

1 . A method of treating or preventing a disease or disorder in an animal caused by infection with  Mycoplasma  hyopneumoniae comprising administering to the animal at from about 3 to about 10 days of age, an effective amount of a single dose of a  Mycoplasma hyopneumoniae  vaccine.  
     
     
         2 . The method according to  claim 1  wherein the animal is a pig.  
     
     
         3 . The method according to  claim 1  wherein the  Mycoplasma hyopneumoniae  vaccine formulation is an inactivated, whole or partial  Mycoplasma hyopneumoniae  cell preparation.  
     
     
         4 . The method of  claim 3  wherein the single dose of the M. hyopneumoniae vaccine contains from about 1×10 6  to about 5×10 10  color changing units (CCU) per dose.  
     
     
         5 . The method of  claim 4  wherein the single dose of the M. hyopneumoniae vaccine contains from about 1×10 8  to 5×10 10  color changing units (CCU) per dose.  
     
     
         6 . The method of  claim 5  wherein the single dose of the M. hyopneumoniae vaccine contains from about 5×10 8  to 5×10 10  color changing units (CCU) per dose.  
     
     
         7 . The method of  claim 3  wherein the amount of said vaccine administered is from about 0.5 to about 3.0 ml.  
     
     
         8 . The method of  claim 3  wherein the amount of said vaccine administered is from about 1.5 ml to about 2.5 ml.  
     
     
         9 . The method of  claim 3  wherein the amount of said vaccine administered is about 2 ml.  
     
     
         10 . The method of  claim 3  wherein the  Mycoplasma hyponeumoniae  cell preparation is RESPISURE-1.  
     
     
         11 . The method of  claim 3  wherein the  Mycoplasma hyponeumoniae  vaccine further comprises a viral or bacterial antigen other than  Mycoplasma hyponeumoniae.    
     
     
         12 . The method of  claim 11  wherein the said viral or bacterial antigens are selected from swine influenza virus (SIV), porcine reproductive and respiratory disease virus (PRRS or mystery swine disease), post-weaning diarrhea (PWD) and porcine proliferative enteritis (ppe).  
     
     
         13 . The method according to  claim 3  wherein said  Mycoplasma hyopneumoniae  preparation is administered intramuscularly.  
     
     
         14 . The method according to  claim 1 , wherein said swine is seropositive for  Mycoplasma hyopneumoniae    
     
     
         15 . The method according to  claim 1 , wherein said swine is seronegative for  Mycoplasma hyopneumoniae.    
     
     
         16 . The method according to  claim 1 , wherein said swine are protected up to 25 weeks following vaccination.  
     
     
         17 . The method according to  claim 1  wherein the  Mycoplasma hyponeumoniae  vaccine further comprises an adjuvant.  
     
     
         18 . The method according to  claim 17  wherein the adjuvant is selected from the group consisting of: mineral gels; surface active substances such as lysolecithin; glycosides comprising saponin or, saponin derivatives such as Quil A or GPI-0100; pluronic polyols; polyanions; non-ionic block polymers, mineral oils, oil emulsions, an emulsion of vegetable oil, water and an emulsifier such as lecithin; alum, cytokines, CpG oligonucleotides, and MDP, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine, N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1′-2′-dipalmitoyl-sn-glycero-3-hydroxyphosphoryloxy)-ethylamine; rmLT, and AMPHIGEN.  
     
     
         19 . The method according to  claim 1  wherein the  Mycoplasma hyponeumoniae  vaccine further comprises a pharmaceutically acceptable carrier.  
     
     
         20 . The method of  claim 1  wherein the  Mycoplasma hyponeumoniae  vaccine is a subunit vaccine.  
     
     
         21 . The method of  claim 20  wherein the subunit vaccine comprises one or more immunogenic polypeptides or proteins or immunogenic fragments of such polypeptides or proteins.  
     
     
         22 . The method of  claim 21  wherein the polypeptides or proteins are selected from the group consisting of: P46, P65, p97, P102, P70, P50 and P44.  
     
     
         23 . The method of  claim 1  wherein the  Mycoplasma hyponeumoniae  vaccine comprises one or more genes or nucleic acids that encode for one or more immunogenic polypeptides or proteins or immunogenic fragments of such polypeptides or proteins and which genes or nucleic acids can be expressed in vivo.  
     
     
         24 . The method of  claim 23  wherein the nucleic acid is DNA.  
     
     
         25 . The method of  claim 23  wherein the genes or nucleic acids are selected from the group consisting of: p46, p65, p97, p102, p70, p50 and p44.  
     
     
         26 . The method of  claim 21  wherein the proteins or polypeptides or immunogenic fragments of such proteins or polypeptides are recombinantly produced.